Results 91 to 100 of about 286,663 (309)
Chemical Bond‐Orchestrated Energy Depletion to Augment Lung Cancer Chemo‐Immunotherapy
Advanced Science, EarlyView.This study grafted dichloroacetic acid (DCA) into perylenediimide (PDI) skeleton via ionic or covalent bond to create novel metabolic agent PDIC‐AC and PDIC‐NAC, explicitly elaborated the underlying energy metabolism and therapeutic mechanism, and developed a promising strategy for energy metabolism‐targeting chemo‐immunotherapy by chemical bond ...
Xuejie Zhao +5 more
wiley +1 more source
MET overexpression and gene amplification in NSCLC: a clinical perspective
, 2013 Lorenza Landi, Gabriele Minuti, Armida D'Incecco, Jessica Salvini, Federico CappuzzoMedical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, ItalyAbstract: The transmembrane tyrosine kinase mesenchymal-epidermal transition (MET)
D'Incecco A +4 more
core
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
, 2015 Martin Reck,1 Anders Mellemgaard2 1Department of Thoracic Oncology, Lung Clinic Grosshansdorf, and member of the Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; 2Department of Oncology, Herlev University Hospital ...
Mellemgaard A +3 more
core +1 more source
Advanced Science, EarlyView.A microfluidic tumor platform integrates pharmacokinetic flow control, vascular‐like barriers, and 3D tumor spheroids to emulate in vivo drug exposure. The system reproduces dynamic concentration–time profiles and enables size‐dependent nanoparticle transport and efficacy evaluation, providing a predictive framework for assessing nanomedicine ...
Su Jeong Kang +5 more
wiley +1 more source
Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs [PDF]
Journal of Pharmacy & Pharmacognosy ResearchContext: Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer type, with 80-85% prevalence. Usually, NSCLC is treated by chemotherapy and radiotherapy in collaboration with gefitinib or other anticancer drugs.
Precella Silvia +2 more
doaj +1 more source
NSCLC patients' characteristics.
, 2014 NSCLC patients' characteristics.
Rui Medeiros (319600) +5 more
core +1 more source
Recent Advances in Immunotherapy in Metastatic NSCLC [PDF]
, 2016 Non-small cell lung cancer (NSCLC) is one of most common malignancies and the leading cause of cancer deaths worldwide. Despite advances in targeted therapies, majority of NSCLC patients do not have targetable genomic alterations.
Gregory N. Gan +6 more
core +1 more source
Advanced Science, EarlyView.A novel dual‐organelle proximity labeling platform, DuO‐SCOUT, decodes the complex landscape of systemic organ‐organ communication by capturing both classical and unconventional secretomes. Application in metabolic models maps the adipose‐to‐brain secretory relay, identifying selective extra‐hypothalamic sites for adipose‐derived factors and expanding ...
Fenglian Yang +7 more
wiley +1 more source
Characteristics of NSCLC patients.
, 2015 Characteristics of NSCLC patients.
Jiaping Chen (103074) +12 more
core +1 more source
Advanced Science, EarlyView.STWave transforms massive microscopic‐resolution spatial transcriptomics into interpretable fine‐scale tissue maps through patch‐wise inference, wavelet‐based multi‐scale encoding, and dual‐domain reconstruction. It reduces noise while preserving weak spatial signals, enabling efficient analysis of 6 40 000 spots of 2.47 GB GPU memory and revealing ...
Tao Jiang +9 more
wiley +1 more source